Telehealth GLP-1 program red flags: the seven warning signs in 2026
Most telehealth programs in our chart are legitimate. A few are racing to the bottom on price by cutting corners that matter. Here are the specific red flags worth checking before you sign up.
TLDR. Most telehealth GLP-1 programs in our chart are legitimate. A few are not. The red flags worth checking before signing up: no licensed prescriber listed, no pharmacy partner disclosed, no clinical intake (a few questions and a credit card), no medical history review, no follow-up cadence, hidden cancellation, hidden price jumps, mandatory long-term prepay, no FDA-registered compounding pharmacy chain of custody, and missing state licensure. Programs racing to the bottom on price often cut at least three of these. Patients pay with bad outcomes when they buy the cheapest path uncritically.
| Fact | Value | Source | Verified |
|---|---|---|---|
| Required licensure visibility | State-licensed prescriber name and number disclosed | State medical board requirements | May 2026 |
| Pharmacy partner disclosure | 503A or 503B name + state license number | FDA compounding guidance | May 2026 |
| Minimum clinical intake | Medical history, current medications, comorbidities, vitals | Telehealth standard of care | May 2026 |
| Required follow-up cadence | Initial 4 to 6 weeks, then quarterly minimum | Obesity medicine guidelines | May 2026 |
| Cash-pay floor where red flags multiply | Below ~$99/mo for compounded suggests pharmacy corner-cutting | Program pricing patterns | May 2026 |
| Cancellation policy disclosure | Must be in plain language on pricing page | FTC Negative Option Rule guidance | May 2026 |
The GLP-1 telehealth market grew 10x in three years. Some of that growth was real-clinical programs scaling responsibly. Some was opportunists racing to the bottom on price by cutting clinical corners that matter. Here are the seven red flags that distinguish the two.
Red flag 1: Same-day prescription with no medical history
If you can sign up at noon, fill out a 5-question form and have a Wegovy script by 3 pm with no review of your existing medications or comorbidities, the program is not practising medicine. They are running a script-filling service.
Legitimate programs require: a real intake covering medications, allergies, prior conditions and weight-loss history; a synchronous or asynchronous visit with a licensed clinician in your state; and at least one lab review or attestation about your baseline metabolic state.
The fastest legitimate onboarding in our chart is 1-2 business days. Anything faster than that should raise a question.
Red flag 2: No clear pharmacy disclosure
For compounded GLP-1 specifically, you should be able to find: the name of the 503A or 503B compounding pharmacy fulfilling your prescription. State board registration. Recent inspection record if you ask.
If the program will not disclose which pharmacy is compounding your medication, that is the warning sign. Reputable programs name their pharmacy partners (Empower, Strive, Olympia, Belmar, Vios, etc.) and link to their pharmacy-board records. Programs that obscure their pharmacy are either using a pharmacy that has compliance problems they don't want you to know about, or a shifting roster of pharmacies they can't guarantee.
Red flag 3: Lock-in contracts longer than 3 months on a first-time GLP-1 patient
Some programs sign first-time GLP-1 patients into 6-month or 12-month commitments at signup, with non-refundable upfront payment. The reasoning offered is "we need to invest in your treatment plan". The actual reasoning is that ~30% of first-time GLP-1 patients quit within 90 days due to side effects, and lock-in transfers that risk to you.
If you have never taken a GLP-1 before, prefer programs with month-to-month billing or a 30-day money-back guarantee. The 6-month plans can come later, once you know you tolerate the molecule. See our best no-lock-in programs.
Red flag 4: No price for higher doses
The standard pricing trick is to advertise a low entry price ($99/mo, $149/mo) that only covers the lowest dose (0.25 mg semaglutide). The actual cost at maintenance dose (2.4 mg) is 2-4x higher. You don't learn the maintenance price until month 5, when switching programs is harder.
Legitimate pricing transparency means publishing the cost at every dose tier on the public pricing page. Flat-pricing programs (same cost at every dose) sidestep this entirely. The chart shows which programs do which; see our cash-pay rankings for predictable-cost programs.
Red flag 5: "Personalised formulations" with no clinical justification
Compounded "personalised formulations" mean adding active ingredients (vitamin B12, l-carnitine) to the semaglutide or tirzepatide preparation. This serves two purposes:
- Legitimate: a pharmacy adds a clinically relevant adjunct because your specific medical situation warrants it.
- Regulatory work-around: a pharmacy adds an inert or near-inert second ingredient so the compound is legally distinct from the FDA-approved drug, allowing 503A compounding to continue after the drug exits the shortage list.
The second reason is what most "personalised formulations" actually are. The added B12 or carnitine doesn't help you lose weight; it threads a regulatory loophole. Knowing this is fine. Being told the B12 has a clinical purpose when it doesn't is the red flag.
Ask your prescriber: "What is the clinical purpose of the B12 in my compounded semaglutide?" If the answer is vague or contradicts what an obesity-medicine specialist would say, the program is reading from a script, not practising medicine.
Red flag 6: No board-certified clinician in your state
Telehealth prescribing requires the prescriber to be licensed in your state. Aggressive low-cost programs sometimes route patients to clinicians in cheaper-license states, which works on the medication-shipping side but creates legal exposure for the patient and clinical-continuity gaps.
The fix is simple: when you sign up, you should see the specific licensed clinician's name and the state they hold a license in. If you can't, the program is intentionally opaque.
For obesity medicine specifically, board certification (ABOM) is the strongest credential. Most programs don't employ ABOM clinicians because they cost more. Programs that do, like Form Health and Knownwell, charge more for it; that price gap reflects real clinical depth.
Red flag 7: Aggressive supplement upselling
A growing pattern in the cheap-end of the market: GLP-1 at near-cost, followed by upsells for "metabolic boosters", "appetite suppressant tinctures", "fat-burning peptides" (often unapproved peptides like AOD-9604 or BPC-157). These are not clinically warranted, the evidence base is thin to non-existent and the program's revenue from them is often higher than from the GLP-1 itself.
The honest version of the same offering would price the GLP-1 at the actual cost and skip the upsells. Programs that hard-upsell supplements in your patient portal or via email after signup are running a multi-product play that goes beyond the disclosed scope.
What to actually do
Before signing up with any program in our chart or outside it, run this checklist:
- Look at the pricing page at every dose tier
- Read the cancellation terms before signup, not after
- Find the name of the compounding pharmacy if compounded
- Find the name of your prescribing clinician and verify their state license
- Check if the program publishes its medical advisor or director (legitimate programs have one; opaque programs don't)
- Search Reddit for "[program name] cancellation" and "[program name] refund". The complaints surface fast.
For programs that pass the checklist, see our scoring methodology and the full chart for the relative ranking.
Frequently asked questions
What is the biggest red flag in a GLP-1 telehealth program?
No clinical intake. A program that takes a credit card and a self-reported BMI without reviewing medical history, current medications, comorbidities, or labs is not practicing medicine; it is mailing prescriptions. Legitimate programs require a documented intake review by a licensed prescriber before the first prescription, even if asynchronous.
How do I know if the prescriber is real?
The program should disclose the prescriber's full name, NPI number, and state license number. Cross-check on the state medical board website. Some programs hide the prescriber behind a brand name and reveal only at intake; that is acceptable. Programs that never disclose are not.
What about the pharmacy partner?
Programs dispensing branded GLP-1 should ship from FDA-registered manufacturer-direct channels (NovoCare, LillyDirect) or licensed retail pharmacies. Programs dispensing compounded should name the 503A pharmacy partner, its state license number, and recent FDA enforcement history. Refusing to name the pharmacy is a flag.
Is a very low cash price a red flag?
Below $99/month for compounded semaglutide is unusual and often signals corner-cutting on pharmacy sourcing, sterility testing, or potency verification. The underlying API cost plus pharmacy labor plus shipping does not compress below that range without removing something safety-relevant. Pay attention if a price looks too good to be true.
What follow-up cadence should I expect?
Standard practice is an initial follow-up at 4 to 6 weeks after the first prescription, then quarterly minimum. Follow-up should include weight, side-effect review, dose discussion, and any concerning symptoms. Programs that prescribe and disappear are not practicing standard-of-care medicine even if the medication itself is genuine.
Programs mentioned in this article
